Treatment with chenodeoxycholic acid in cerebrotendinous xanthomatosis: clinical, neurophysiological, and quantitative brain structural outcomes.

J Inherit Metab Dis 2018 09 20;41(5):799-807. Epub 2018 Mar 20.

Centre de Référence Neurométabolique Adulte, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Background: Cerebrotendinous xanthomatosis (CTX) is a rare neurodegenerative disease related to sterols metabolism. It affects both central and peripheral nervous systems but treatment with chenodeoxycholic acid (CDCA) has been reported to stabilize clinical scores and improve nerve conduction parameters. Few quantitative brain structural studies have been conducted to assess the effect of CDCA in CTX.

Methods And Results: We collected retrospectively clinical, neurophysiological, and quantitative brain structural data in a cohort of 14 patients with CTX treated by CDCA over a mean period of 5 years. Plasma cholestanol levels normalized under treatment with CDCA within a few months. We observed a significant clinical improvement in patients up to 25 years old, whose treatment was initiated less than 15 years after the onset of neurological symptoms. Conversely, patients whose treatment was initiated more than 25 years after neurological disease onset continued their clinical deterioration. Eleven patients presented with a length-dependent peripheral neuropathy, whose electrophysiological parameters improved significantly under CDCA. Volumetric analyses in a subset of patients showed no overt volume loss under CDCA. Moreover, diffusion weighted imaging showed improved fiber integrity of the ponto-cerebellar and the internal capsule with CDCA. CDCA was well tolerated in all patients with CTX.

Conclusion: CDCA may reverse the pathophysiological process in patients with CTX, especially if treatment is initiated early in the disease process. Besides tendon xanthoma, this study stresses the need to consider plasma cholestanol measurement in any patient with infantile chronic diarrhea and/or jaundice, juvenile cataract, learning disability and/or autism spectrum disorder, pyramidal signs, cerebellar syndrome or peripheral neuropathy.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10545-018-0162-7DOI Listing
September 2018
24 Reads

Publication Analysis

Top Keywords

treatment initiated
12
quantitative brain
12
brain structural
12
cdca
9
neurophysiological quantitative
8
plasma cholestanol
8
peripheral neuropathy
8
clinical neurophysiological
8
patients ctx
8
cerebrotendinous xanthomatosis
8
treatment chenodeoxycholic
8
chenodeoxycholic acid
8
patients
7
treatment
6
clinical
5
cdca volumetric
4
parameters improved
4
improved cdca
4
neuropathy electrophysiological
4
presented length-dependent
4

References

(Supplied by CrossRef)

F Barkhof et al.
Radiology 2000

VM Berginer et al.
N Engl J Med 1984

VM Berginer et al.
J Neurol Sci 1994

CC Chang et al.
BMC Neurol 2010

B Degos et al.
Orphanet J Rare Dis 2016

F Ginanneschi et al.
J Neurol 2013

S Guerrera et al.
J Neurol Neurosurg Psychiatry 2010

A Honda et al.
J Lipid Res 2008

M Inglese et al.
Am J Neuroradiol 2003

K Inoue et al.
Biochem Biophys Res Commun 1999

Similar Publications